Atyr Pharma Inc (NASDAQ: ATYR) has experienced a rise in its stock price by 10.39 compared to its previous closing price of 3.08. However, the company has seen a fall of -14.03% in its stock price over the last five trading days. globenewswire.com reported 2025-03-06 that SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the outcome of a fourth, pre-planned interim safety analysis conducted by an independent data and safety monitoring board (DSMB) for the ongoing Phase 3 EFZO-FIT™ study of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. The DSMB recommended that the study continue without any modifications.
Is It Worth Investing in Atyr Pharma Inc (NASDAQ: ATYR) Right Now?
ATYR has 36-month beta value of 0.93. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATYR is 81.24M, and currently, short sellers hold a 5.36% ratio of that float. The average trading volume of ATYR on March 10, 2025 was 1.12M shares.
ATYR’s Market Performance
The stock of Atyr Pharma Inc (ATYR) has seen a -14.03% decrease in the past week, with a -13.71% drop in the past month, and a 2.10% gain in the past quarter. The volatility ratio for the week is 13.89%, and the volatility levels for the past 30 days are at 9.29% for ATYR. The simple moving average for the past 20 days is -8.16% for ATYR’s stock, with a 30.32% simple moving average for the past 200 days.
Analysts’ Opinion of ATYR
Many brokerage firms have already submitted their reports for ATYR stocks, with Leerink Partners repeating the rating for ATYR by listing it as a “Outperform.” The predicted price for ATYR in the upcoming period, according to Leerink Partners is $16 based on the research report published on February 18, 2025 of the current year 2025.
Wells Fargo gave a rating of “Overweight” to ATYR, setting the target price at $17 in the report published on October 04th of the previous year.
ATYR Trading at -7.37% from the 50-Day Moving Average
After a stumble in the market that brought ATYR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.04% of loss for the given period.
Volatility was left at 9.29%, however, over the last 30 days, the volatility rate increased by 13.89%, as shares sank -12.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.49% upper at present.
During the last 5 trading sessions, ATYR fell by -14.03%, which changed the moving average for the period of 200-days by +70.00% in comparison to the 20-day moving average, which settled at $3.70. In addition, Atyr Pharma Inc saw -6.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATYR starting from Broadfoot Jill Marie, who sale 1,254 shares at the price of $3.78 back on Feb 04 ’25. After this action, Broadfoot Jill Marie now owns 31,763 shares of Atyr Pharma Inc, valued at $4,740 using the latest closing price.
DENYES NANCY, the General Counsel of Atyr Pharma Inc, sale 899 shares at $3.78 during a trade that took place back on Feb 04 ’25, which means that DENYES NANCY is holding 26,555 shares at $3,398 based on the most recent closing price.
Stock Fundamentals for ATYR
Current profitability levels for the company are sitting at:
- -289.59 for the present operating margin
- -5.64 for the gross margin
The net margin for Atyr Pharma Inc stands at -271.56. The total capital return value is set at -0.88. Equity return is now at value -77.96, with -58.90 for asset returns.
Based on Atyr Pharma Inc (ATYR), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -4.94.
Currently, EBITDA for the company is -52.18 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 1223.47. The receivables turnover for the company is 0.13for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.41.
Conclusion
To put it simply, Atyr Pharma Inc (ATYR) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
